Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Intismeran Autogene · mRNA-4157, V940

Vaccine (mRNA vaccine) · Immune activation, directed at neoantigens · developed by Merck Sharp & Dohme LLC

Phase 3 Most advanced trial

MRK Developer

2 Registered trials

What is Intismeran Autogene?

Intismeran autogene is an mRNA vaccine encoding patient-specific neoantigen epitopes encapsulated in lipid nanoparticles. It is designed to activate cytotoxic T-lymphocyte and memory T-cell responses against the patient's cancer cells expressing these neoantigens. It is studied in non-small-cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: mRNA-4157, V940, Intismeran
Drug type: Vaccine (mRNA vaccine)
Targets: neoantigens (antigen)
Mechanism: Immune activation, directed at neoantigens
Pathways: MHC presentation, CTL activation, memory T-cell response
Therapy area: Oncology
Developer: Merck Sharp & Dohme LLC (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: ZG6U44T8SG

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07513376	Phase 3	Non-small Cell Lung Cancer	Recruiting	MRK
NCT06623422	Phase 3	Carcinoma, Non-Small-Cell Lung	Recruiting	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Non-Small-Cell LungNon-small Cell Lung Cancer

More from Merck Sharp & Dohme LLC

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Intismeran Autogene

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z